Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17230099 | 0.93 | HTT (0.43) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL27250878 | 0.92 | HTT (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL24879380 | 0.92 | HTT (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL20510404 | 0.87 | MEN1 (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL18513370 | 0.87 | HTT (0.41) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL26879992 | 0.86 | MEN1 (0.44) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL22537924 | 0.86 | HTT (0.38) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL20968825 | 0.86 | ALDH1A1 (0.39) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL25985210 | 0.85 | FOLH1 (0.41) | POLBHTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL5050709 | 0.84 | HTT (0.57) | MEN1KMT2AMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3600381-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175272-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, IAPP, INSR | MEN1 766/4885KMT2A 3495/4885MAPT 1743/4885 |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | GPR119, IAPP, INSR | MEN1 766/4885KMT2A 3495/4885MAPT 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.